CCR2 and central nervous system cancer: In GSCs, celecoxib revealed significant decrease in mRNA levels of Ccl2 and Cxcr3 but not of Ccr2 and Cxcl10 (Fig. 4a), which was consistent with the high mRNA levels of Ccl2 in the glioma model and GSCs but none of Cxcl10 in GSCs (Fig. 4b).